Infant Bacterial Therapeutics AB (publ)

BST:9IB Stock Report

Market Cap: €69.8m

Infant Bacterial Therapeutics Management

Management criteria checks 3/4

Infant Bacterial Therapeutics' CEO is Staffan Stromberg, appointed in Jan 2013, has a tenure of 12.33 years. total yearly compensation is SEK6.06M, comprised of 53.7% salary and 46.3% bonuses, including company stock and options. directly owns 0.79% of the company’s shares, worth €554.32K. The average tenure of the management team and the board of directors is 2 years and 8 years respectively.

Key information

Staffan Stromberg

Chief executive officer

SEK 6.1m

Total compensation

CEO salary percentage53.71%
CEO tenure12.3yrs
CEO ownership0.8%
Management average tenure2yrs
Board average tenure8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Staffan Stromberg's remuneration changed compared to Infant Bacterial Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-SEK 126m

Dec 31 2024SEK 6mSEK 3m

-SEK 137m

Sep 30 2024n/an/a

-SEK 144m

Jun 30 2024n/an/a

-SEK 142m

Mar 31 2024n/an/a

-SEK 128m

Dec 31 2023SEK 5mSEK 3m

-SEK 123m

Sep 30 2023n/an/a

-SEK 122m

Jun 30 2023n/an/a

-SEK 99m

Mar 31 2023n/an/a

-SEK 69m

Dec 31 2022SEK 6mSEK 3m

-SEK 65m

Sep 30 2022n/an/a

-SEK 42m

Jun 30 2022n/an/a

-SEK 34m

Mar 31 2022n/an/a

-SEK 65m

Dec 31 2021SEK 5mSEK 3m

-SEK 45m

Sep 30 2021n/an/a

-SEK 55m

Jun 30 2021n/an/a

-SEK 74m

Mar 31 2021n/an/a

-SEK 73m

Dec 31 2020SEK 4mSEK 2m

-SEK 72m

Sep 30 2020n/an/a

-SEK 73m

Jun 30 2020n/an/a

-SEK 65m

Mar 31 2020n/an/a

-SEK 44m

Dec 31 2019SEK 3mSEK 2m

-SEK 46m

Sep 30 2019n/an/a

-SEK 43m

Jun 30 2019n/an/a

-SEK 40m

Mar 31 2019n/an/a

-SEK 32m

Dec 31 2018SEK 3mSEK 2m

-SEK 41m

Compensation vs Market: Staffan's total compensation ($USD622.72K) is about average for companies of similar size in the German market ($USD491.43K).

Compensation vs Earnings: Staffan's compensation has increased whilst the company is unprofitable.

CEO

Staffan Stromberg (57 yo)

12.3yrs

Tenure

SEK 6,057,000

Compensation

Mr. Staffan Stromberg, Ph.D. Eng has been the Chief Executive Officer at Infant Bacterial Therapeutics AB (publ) since 2013. Mr. Stromberg served as Director at Genetic Analysis AS since October 28, 2020 u...

Leadership Team

NamePositionTenureCompensationOwnership
Staffan Stromberg
Chief Executive Officer12.3yrsSEK 6.06m0.79%
€ 554.3k
Maria Ekdahl
Chief Financial Officer2.7yrsno data0.026%
€ 17.9k
Anders Kronström
Chief Operating Officer7.3yrsSEK 500.00k0.083%
€ 58.0k
Thomas Schnitzer
Chief Scientific Officer1.3yrsno datano data
Sanjiv Sharma
Head of Medical Affairs1.3yrsno datano data
Jonas Rastad
Chief Medical Officer1.3yrsno datano data

2.0yrs

Average Tenure

57yo

Average Age

Experienced Management: 9IB's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Peter Rothschild
Chairman14.3yrsSEK 747.00kno data
Margareta Hagman
Independent Director9.7yrsSEK 188.00k0.039%
€ 27.4k
Eva Idén
Independent Director8yrsSEK 163.00k0.0042%
€ 2.9k
Kristina Nygren
Independent Director7yrsSEK 163.00k0.00074%
€ 516.9
Anthon Jahreskog
Director8yrsSEK 218.00k0.18%
€ 125.8k

8.0yrs

Average Tenure

58yo

Average Age

Experienced Board: 9IB's board of directors are considered experienced (8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/14 23:38
End of Day Share Price 2025/03/31 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Infant Bacterial Therapeutics AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.